Efficacy and safety of risankizumab for the treatment of palmoplantar pustulosis – findings from the phase 3 JumPPP study: Yukari Okubo

Palmoplantar pustulosis is an uncommon chronic pustular condition affecting the palms and soles, with use of biologic therapies linked in its development.  touchDERMATOLOGY were delighted to speak with Prof. Yukari Okubo (Tokyo Medical University, Tokyo, Japan) to discuss the phase 3 JUMPPP 68 week results investigating the efficacy and safety of risankizumab for the treatment of palmoplantar pustulosis in Japanese patients. The abstract ‘Efficacy and Safety of Risankizumab for the Treatment of Moderate-to-Severe Palmoplantar Pustulosis in Japanese Patients: 68-week Data From the Phase 3 JumPPP Study.' (Abstract number: 3008) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress. Questions: What is known about the clinical utility of risankizumab in the treatment of palmoplantar pustulosis? What were the aims, design, and eligibility criteria for the phase 3 JUMPPP study? What were the efficacy findings of the study? Could you elaborate on the safety findings and any notable differences or similarities with other studies involving risankizumab? How do these results contribute to our understanding of the long-term effectiveness of risankizumab in the treatment of palmoplantar pustulosis, especially in the context of Japanese adults? What do you think are the next steps or areas of research that should be explored based on the outcomes of this study? Disclosures: Prof. Yukari Okubo has no actual or potential conflicts of interest in relation to this video, or in connection with the (EFPIA) HCP Code. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress.